Multiplex fluorescent IHC for CD8a, F4/80, CD86 and PD-L1 was used to evaluate the landscape of the HCC immune microenvironment to explore the mechanisms underlying the different response patterns for aPD-1 and HLS@SVMAV treatments (figure 7G). Here, CD86 is linked to hepatocellular carcinoma.